Search

Your search keyword '"Benten, D"' showing total 17 results
Start Over Author "Benten, D" Journal journal of hepatology
17 results on '"Benten, D"'

2. The kynurenine pathway in cirrhosis. Relationship with the development of acute decompensation and acute-on-chronic liver failure, clinical course and mortality

Author

Clària, J., primary, Moreau, R., additional, Fenaille, F., additional, Amoros, A., additional, Junot, C., additional, Gronbaek, H., additional, Coenraad, M., additional, Oettl, K., additional, Caraceni, P., additional, Alessandria, C., additional, Trebicka, J., additional, Pavesi, M., additional, Gomez, C.D., additional, Albillos, A., additional, Gustot, T., additional, Welzel, T., additional, Fernandez, J., additional, Stauber, R.E., additional, Saliba, F., additional, Butin, N., additional, Colsch, B., additional, Moreno, C., additional, Durand, F., additional, Nevens, F., additional, Bañares, R., additional, Benten, D., additional, Ginès, P., additional, Gerbes, A., additional, Jalan, R., additional, Angeli, P., additional, Bernardi, M., additional, and Arroyo, V., additional

Published
2018
Full Text
View/download PDF

3. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure

Author

Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P, Hopf C, Alessandria C, Rodriguez E, Solis Muñoz P, Laleman W, Trebicka J, Zeuzem S. Albillos A, Gustot T, Mookerjee R, Elkrief L, Benten D, Montero JL, Catalina MV, Concepción M, Cordoba J, McCormick A, Stauber R, Vogel W, De Gottardi A, Peck Radosavljevic M, Van Vlierberghe H, Sperl J, Groenbaek H, Mortensen C, Coenraad MJ, Morando F, Gerbes AL, Risso A, Garcia E, Deulofeu C, Samuel D, Arroyo V., ZACCHERINI, GIACOMO, CARACENI, PAOLO, BERNARDI, MAURO, Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Muñoz P, Laleman W, Trebicka J, Zeuzem S. Albillos A, Gustot T, Mookerjee R, Elkrief L, Benten D, Montero JL, Catalina MV, Concepción M, Cordoba J, McCormick A, Stauber R, Vogel W, De Gottardi A, Peck-Radosavljevic M, Van Vlierberghe H, Sperl J, Groenbaek H, Mortensen C, Coenraad MJ, Morando F, Gerbes AL, Risso A, Garcia E, Deulofeu C, Samuel D, Bernardi M, and Arroyo V.

Subjects
Adult, Liver Cirrhosis, Male, medicine.medical_specialty, Cirrhosis, Time Factors, Databases, Factual, Multi-organ failure, Severity of Illness Index, Cohort Studies, Databases, Internal medicine, Intensive care, Sepsis, Severity of illness, medicine, Risk of mortality, Humans, Decompensation, Intensive care medicine, Hepatic encephalopathy, Factual, Aged, Hepatology, business.industry, Acute-on chronic liver failure, Acute-On-Chronic Liver Failure, Middle Aged, medicine.disease, Prognosis, body regions, Europe, Acute-on-chronic liver failure, Cohort, Female, business, Cohort study
Abstract

Background & Aims: Acute-on-chronic liver failure (ACLF) is a frequent syndrome (30% prevalence), characterized by acute decompensation of cirrhosis, organ failure(s) and high short-term mortality. This study develops and validates a specific prognostic score for ACLF patients. Methods: Data from 1349 patients included in the CANONIC study were used. First, a simplified organ function scoring system (CLIF Consortium Organ Failure score, CLIF-C OFs) was developed to diagnose ACLF using data from all patients. Subsequently, in 275 patients with ACLF, CLIP-C OFs and two other independent predictors of mortality (age and white blood cell count) were combined to develop a specific prognostic score for ACLF (CLIF Consortium ACLF score [CLIF-C ACLFs]). A concordance index (C-index) was used to compare the discrimination abilities of CLIF-C ACLF, MELD, MELD-sodium (MELD-Na), and Child-Pugh (CPs) scores. The CLIF-C ACLFs was validated in an external cohort and assessed for sequential use. Results: The CLIF-C ACLFs showed a significantly higher predictive accuracy than MELDs, MELD-Nas, and CPs, reducing (19-28%) the corresponding prediction error rates at all main time points after ACLF diagnosis (28, 90, 180, and 365 days) in both the CANONIC and the external validation cohort. CLIF-C ACLFs computed at 48 h, 3-7 days, and 8-15 days after ACLF diagnosis predicted the 28-day mortality significantly better than at diagnosis. Conclusions: The CLIF-C ACLFs at ACLF diagnosis is superior to the MELDs and MELD-Nas in predicting mortality. The CLIP-C ACLFs is a clinically relevant, validated scoring system that can be used sequentially to stratify the risk of mortality in ACLF patients. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Published
2014

5. LBP-028 - The kynurenine pathway in cirrhosis. Relationship with the development of acute decompensation and acute-on-chronic liver failure, clinical course and mortality

Author

Clària, J., Moreau, R., Fenaille, F., Amoros, A., Junot, C., Gronbaek, H., Coenraad, M., Oettl, K., Caraceni, P., Alessandria, C., Trebicka, J., Pavesi, M., Gomez, C.D., Albillos, A., Gustot, T., Welzel, T., Fernandez, J., Stauber, R.E., Saliba, F., Butin, N., Colsch, B., Moreno, C., Durand, F., Nevens, F., Bañares, R., Benten, D., Ginès, P., Gerbes, A., Jalan, R., Angeli, P., Bernardi, M., and Arroyo, V.

Published
2018
Full Text
View/download PDF

7. P476 SHORT-TERM (28-DAY) CLINICAL COURSE AND TRANSPLANT-FREE MORTALITY IN ACUTE ON CHRONIC LIVER FAILURE (ACLF); EVIDENCE FOR REVERSIBILITY OF ACLF (A STUDY FROM THE CANONIC DATABASE)

Author

Gustot, T., primary, Fernandez, J., additional, Garcia, E., additional, Ginès, P., additional, Moreau, R., additional, Jalan, R., additional, Pavesi, M., additional, Durand, F., additional, Angeli, P., additional, Caraceni, P., additional, Markwardt, D., additional, Alessandria, C., additional, Solis Muñoz, P., additional, Laleman, W., additional, Trebicka, J., additional, Saliba, F., additional, Zeuzem, S., additional, Albillos, A., additional, Elkrief, L., additional, Benten, D., additional, Montero, J.L., additional, Chiva, M.T., additional, Concepcion, M., additional, Cordoba, J., additional, McCormick, A., additional, Stauber, R.E., additional, Vogel, W., additional, de Gottardi, A., additional, Morando, F., additional, Domenicali, M., additional, Gerbes, A., additional, Risso, A., additional, Deulofeu, C., additional, Bernardi, M., additional, and Arroyo, V., additional

Published
2014
Full Text
View/download PDF

8. 1414 THE CLIF-CONSORTIUM SCORE PREDICTS MORTALITY MORE ACCURATELY THAN THE MELD AND MELD-SODIUM SCORES IN PATIENTS HOSPITALIZED WITH DECOMPENSATED CIRRHOSIS WITH AND WITHOUT ACUTE-ON-CHRONIC-LIVER FAILURE (ACLF).

Author

Pavesi, M., primary, Jalan, R., additional, Amoros, A., additional, Moreau, R., additional, Ginès, P., additional, Durand, F., additional, Angeli, P., additional, Caraceni, P., additional, Rodriguez, E., additional, Agarwarl, B., additional, Hopf, C., additional, Alessandria, C., additional, Solis-Muñoz, P., additional, Laleman, W., additional, Trebicka, J., additional, Saliba, F., additional, Zeuzem, S., additional, Albillos, A., additional, Gustot, T., additional, Mookerjee, R., additional, Elkrief, L., additional, Benten, D., additional, Montero, J.L., additional, Catalina, M.V., additional, Concepción, M., additional, Cordoba, J., additional, McCormick, A., additional, Stauber, R., additional, Vogel, W., additional, De Gottardi, A., additional, Peck-Radosavljevic, M., additional, van Vlierberghe, H., additional, Sperl, J., additional, Groenbaek, H., additional, Mortensen, C., additional, Coenraad, M.J., additional, Morando, F., additional, Domenicali, M., additional, Gerbes, A., additional, Risso, A., additional, Garcia, E., additional, Deulofeu, C., additional, Bernardi, M., additional, and Arroyo, V., additional

Published
2013
Full Text
View/download PDF

11. 1404 DIAGNOSIS, PREVALENCE, AND PROGNOSIS OF ACUTE-ON- CHRONIC LIVER FAILURE (ACLF): RESULTS OF THE EASL-CHRONIC LIVER FAILURE (CLIF) CONSORTIUM CANONIC STUDY

Author

Moreau, R., primary, Gines, P., additional, Jalan, R., additional, Pavesi, M., additional, Durand, F., additional, Angeli, P., additional, Caraceni, P., additional, Pereira, G., additional, Hopf, C., additional, Alessandria, C., additional, Solis, P., additional, Laleman, W., additional, Trebicka, J., additional, Saliba, F., additional, Zeuzem, S., additional, Albillos, A., additional, Gustot, T., additional, Yago, M., additional, Elkrief, L., additional, Benten, D., additional, Montero, J.-L., additional, Chiva, T., additional, Concepción, M., additional, Cordoba, J., additional, McCormick, A., additional, Stauber, R.-E., additional, Vogel, W., additional, De Gottardi, A., additional, Morando, F., additional, Domenicali, M., additional, Gerbes, A.-L., additional, Risso, A., additional, García, E., additional, Deulofeu, C., additional, Bernardi, M., additional, and Arroyo, V., additional

Published
2012
Full Text
View/download PDF

12. 515 LENTIVIRAL ‘GENE ONTOLOGY’ (LEGO) VECTORS ENABLE HIGHLY EFFICIENT EX VIVO TRANSDUCTION OF HEPATOCYTES SUITABLE FOR CELL TRANSPLANTATION

Author

Warlich, M., primary, Weber, K., additional, Thomaschewski, M., additional, Lütgehetmann, M., additional, Volz, T., additional, Pollok, J.M., additional, Gersting, S., additional, Borsch, J., additional, Santer, R., additional, Ullrich, K., additional, Lohse, A.W., additional, Dandri, M., additional, Fehse, B., additional, and Benten, D., additional

Published
2011
Full Text
View/download PDF

14. Correction to 'Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF' [J Hepatol 2020 (72) 688-701].

Author

Moreau R, Clària J, Aguilar F, Fenaille F, Lozano JJ, Junot C, Colsch B, Caraceni P, Trebicka J, Pavesi M, Alessandria C, Nevens F, Saliba F, Welzel TM, Albillos A, Gustot T, Fernández J, Moreno C, Baldassarre M, Zaccherini G, Piano S, Montagnese S, Vargas V, Genescà J, Solà E, Bernal W, Butin N, Hautbergue T, Cholet S, Castelli F, Jansen C, Steib C, Campion D, Mookerjee R, Rodríguez-Gandía M, Soriano G, Durand F, Benten D, Bañares R, Stauber RE, Gronbaek H, Coenraad MJ, Ginès P, Gerbes A, Jalan R, Bernardi M, Arroyo V, and Angeli P

Published
2020
Full Text
View/download PDF

15. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF.

Author

Moreau R, Clària J, Aguilar F, Fenaille F, Lozano JJ, Junot C, Colsch B, Caraceni P, Trebicka J, Pavesi M, Alessandria C, Nevens F, Saliba F, Welzel TM, Albillos A, Gustot T, Fernández J, Moreno C, Baldassarre M, Zaccherini G, Piano S, Montagnese S, Vargas V, Genescà J, Solà E, Bernal W, Butin N, Hautbergue T, Cholet S, Castelli F, Jansen C, Steib C, Campion D, Mookerjee R, Rodríguez-Gandía M, Soriano G, Durand F, Benten D, Bañares R, Stauber RE, Gronbaek H, Coenraad MJ, Ginès P, Gerbes A, Jalan R, Bernardi M, Arroyo V, and Angeli P

Subjects
Adult, Aged, Biomarkers blood, Case-Control Studies, Female, Humans, Inflammation metabolism, Male, Middle Aged, Prospective Studies, Severity of Illness Index, Acute-On-Chronic Liver Failure blood, Acute-On-Chronic Liver Failure complications, Glycolysis, Liver Cirrhosis blood, Liver Cirrhosis complications, Metabolome, Metabolomics methods, Mitochondria metabolism
Abstract

Background & Aims: Acute-on-chronic liver failure (ACLF), which develops in patients with cirrhosis, is characterized by intense systemic inflammation and organ failure(s). Because systemic inflammation is energetically expensive, its metabolic costs may result in organ dysfunction/failure. Therefore, we aimed to analyze the blood metabolome in patients with cirrhosis, with and without ACLF., Methods: We performed untargeted metabolomics using liquid chromatography coupled to high-resolution mass spectrometry in serum from 650 patients with AD (acute decompensation of cirrhosis, without ACLF), 181 with ACLF, 43 with compensated cirrhosis, and 29 healthy individuals., Results: Of the 137 annotated metabolites identified, 100 were increased in patients with ACLF of any grade, relative to those with AD, and 38 comprised a distinctive blood metabolite fingerprint for ACLF. Among patients with ACLF, the intensity of the fingerprint increased across ACLF grades, and was similar in patients with kidney failure and in those without, indicating that the fingerprint reflected not only decreased kidney excretion but also altered cell metabolism. The higher the ACLF-associated fingerprint intensity, the higher the plasma levels of inflammatory markers, tumor necrosis factor α, soluble CD206, and soluble CD163. ACLF was characterized by intense proteolysis and lipolysis; amino acid catabolism; extra-mitochondrial glucose metabolism through glycolysis, pentose phosphate, and D-glucuronate pathways; depressed mitochondrial ATP-producing fatty acid β-oxidation; and extra-mitochondrial amino acid metabolism giving rise to metabotoxins., Conclusions: In ACLF, intense systemic inflammation is associated with blood metabolite accumulation and profound alterations in major metabolic pathways, in particular inhibition of mitochondrial energy production, which may contribute to the development of organ failures., Lay Summary: Acute-on-chronic liver failure (ACLF), which develops in patients with cirrhosis, is characterized by intense systemic inflammation and organ failure(s). Because systemic inflammation is energetically expensive, its metabolic costs may result in organ dysfunction/failure. We identified a 38-metabolite blood fingerprint specific for ACLF that revealed mitochondrial dysfunction in peripheral organs. This may contribute to organ failures., (Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)

Published
2020
Full Text
View/download PDF

16. Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis.

Author

Solà E, Kerbert AJ, Verspaget HW, Moreira R, Pose E, Ruiz P, Cela R, Morales-Ruiz M, López E, Graupera I, Solé C, Huelin P, Navarro AA, Ariza X, Jalan R, Fabrellas N, Benten D, de Prada G, Durand F, Jimenez W, van der Reijden JJ, Fernandez J, van Hoek B, Coenraad MJ, and Ginès P

Subjects
Biomarkers, Disease Progression, Glycopeptides, Humans, Prognosis, Prospective Studies, Liver Cirrhosis
Abstract

Background & Aims: Research on vasopressin (AVP) in cirrhosis and its role in the assessment of prognosis has been hindered by the difficulty of measuring AVP levels accurately. Copeptin, a 39-aminoacid glycopeptide, is released from the neurohypophysis together with AVP. Copeptin could have a role as biomarker of prognosis in cirrhosis as it may reflect circulatory dysfunction. The aim of this study is to investigate the role of copeptin as biomarker of disease progression and prognosis in cirrhosis., Methods: This prospective study is divided in 2 study protocols including 321 consecutive patients. Plasma copeptin levels were measured in all patients at study inclusion. Protocol 1: to investigate the relationship of copeptin with kidney and circulatory function (56 patients). Protocol 2: to investigate the relationship between copeptin and prognosis, as assessed by the development of complications of cirrhosis or mortality at 3months (265 patients admitted to hospital for complications of cirrhosis)., Results: Patients with decompensated cirrhosis showed significantly higher plasma copeptin levels compared to those of patients with compensated cirrhosis. Copeptin levels had a significant positive correlation with model for end-satge liver disease (MELD) score, AVP, endogenous vasoconstrictor systems, and kidney function parameters. Patients developing complications of cirrhosis or mortality had significantly higher plasma copeptin levels compared to those of the remaining patients. Plasma copeptin levels were an independent predictive factor of both the development of complications and mortality at 3months. This was confirmed in a validation series of 120 patients., Conclusions: Copeptin is a novel biomarker of disease progression and prognosis in cirrhosis., Lay Summary: Copeptin is a fragment of the vasopressin precursor, a hormone that is known to be increased in patients with cirrhosis and that plays a role in the development of complications of the disease. Vasopressin is difficult to measure, but copeptin is a more stable molecule and is easier to measure in blood. Solà and Kerbert and colleagues have shown in a series of 361 patients that copeptin is markedly increased in patients with cirrhosis who develop complications during the following 3months, compared to those patients who do not develop complications. Moreover, copeptin correlates with prognosis., (Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results